DE69330960D1 - Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil - Google Patents

Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil

Info

Publication number
DE69330960D1
DE69330960D1 DE69330960T DE69330960T DE69330960D1 DE 69330960 D1 DE69330960 D1 DE 69330960D1 DE 69330960 T DE69330960 T DE 69330960T DE 69330960 T DE69330960 T DE 69330960T DE 69330960 D1 DE69330960 D1 DE 69330960D1
Authority
DE
Germany
Prior art keywords
blood coagulation
normalizer
active ingredient
containing tcf
coagulation containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330960T
Other languages
English (en)
Other versions
DE69330960T2 (de
Inventor
Hiroaki Masunaga
Nobuaki Fujise
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Pharmaceuticals Inc Sunnyvale Calif Us
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Publication of DE69330960D1 publication Critical patent/DE69330960D1/de
Application granted granted Critical
Publication of DE69330960T2 publication Critical patent/DE69330960T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69330960T 1992-07-16 1993-07-14 Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil Expired - Fee Related DE69330960T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21222892 1992-07-16
JP11780993 1993-04-21
PCT/JP1993/000974 WO1994002165A1 (en) 1992-07-16 1993-07-14 Blood coagulation normalizer containing tcf-ii as active ingredient

Publications (2)

Publication Number Publication Date
DE69330960D1 true DE69330960D1 (de) 2001-11-22
DE69330960T2 DE69330960T2 (de) 2002-04-11

Family

ID=26455863

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330960T Expired - Fee Related DE69330960T2 (de) 1992-07-16 1993-07-14 Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil

Country Status (11)

Country Link
US (1) US5714461A (de)
EP (1) EP0653211B1 (de)
JP (1) JP3634359B2 (de)
KR (1) KR100260964B1 (de)
AT (1) ATE206929T1 (de)
AU (1) AU674871B2 (de)
CA (1) CA2140010C (de)
DE (1) DE69330960T2 (de)
DK (1) DK0653211T3 (de)
ES (1) ES2165855T3 (de)
WO (1) WO1994002165A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020214A1 (fr) * 1994-12-27 1996-07-04 Snow Brand Milk Products Co., Ltd. Mutant de tcf
WO1997012628A1 (en) * 1995-10-05 1997-04-10 Genentech, Inc. Methods and compositions for treating vascular stenosis
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ZA982068B (en) 1997-03-14 1998-09-16 Snow Brand Milk Products Co Ltd Agent for preventing and/or treating cachexia
JPH1129493A (ja) * 1997-07-14 1999-02-02 Snow Brand Milk Prod Co Ltd 放射線障害予防及び／又は治療剤
JPH11269091A (ja) * 1998-03-19 1999-10-05 Snow Brand Milk Prod Co Ltd 敗血症予防及び／又は治療剤
US7741452B2 (en) 2003-12-16 2010-06-22 Toshikazu Nakamura Glycosylation-deficient hepatocyte growth factor
US7262637B2 (en) * 2005-03-22 2007-08-28 Micron Technology, Inc. Output buffer and method having a supply voltage insensitive slew rate
US20230270792A1 (en) * 2020-08-12 2023-08-31 Figene, Llc Reduction of covid-19 coagulopathy and other inflammation-associated coagulopathies by administration of fibroblasts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076701A (en) * 1975-07-29 1978-02-28 Immunology Research Foundation, Inc. Tumor complement fraction recovery method and product
US4490549A (en) * 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
JPH0296598A (ja) * 1988-10-03 1990-04-09 Sapporo Breweries Ltd リンフォカイン活性化キラー細胞誘導抑制因子ｌａｋｓｆ，その製造法およびそれを有効成分とする免疫抑制剤
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
DE69131069T2 (de) * 1990-07-13 1999-07-15 Snow Brand Milk Products Co., Ltd., Sapporo, Hokkaido Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
JPH0597A (ja) * 1991-06-21 1993-01-08 Snow Brand Milk Prod Co Ltd 新規抗ｔｃｆ−ｉｉモノクローナル抗体及びそれを用いるｔｃｆ−ｉｉの測定方法
EP0588477B1 (de) * 1992-07-16 1997-10-15 Snow Brand Milk Products Co., Ltd. Arzneimittelzusammensetzung enthaltend TCF-II
WO1994014845A1 (en) * 1992-12-28 1994-07-07 Snow Brand Milk Products Co., Ltd. Modified tcf
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤

Also Published As

Publication number Publication date
ES2165855T3 (es) 2002-04-01
AU674871B2 (en) 1997-01-16
JP3634359B2 (ja) 2005-03-30
EP0653211A1 (de) 1995-05-17
US5714461A (en) 1998-02-03
EP0653211A4 (de) 1996-06-26
WO1994002165A1 (en) 1994-02-03
ATE206929T1 (de) 2001-11-15
KR100260964B1 (ko) 2000-07-01
DK0653211T3 (da) 2002-05-06
KR950702433A (ko) 1995-07-29
AU4583393A (en) 1994-02-14
CA2140010A1 (en) 1994-02-03
DE69330960T2 (de) 2002-04-11
CA2140010C (en) 2008-04-01
EP0653211B1 (de) 2001-10-17

Similar Documents

Publication Publication Date Title
ATE290867T1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
ATE136030T1 (de) Azaheterocyclylmethyl-chromane als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
DE69733826D1 (de) Behandlung von leukocyten durch photopheresis
ES2111579T3 (es) Preparaciones de factor viii estabilizadas.
DE3851711D1 (de) Verwendung von Morphinantagonisten zur Herstellung von Medikamenten mit immunmodulatorischer und antiviraler Wirkung, insbesondere bestimmt zur Behandlung von erworbenen Immunmangelzuständen.
DE59307717D1 (de) Fungizide Mischungen auf der Basis von Triazol-Fungiziden und 4,6-Dimethyl-N-Phenyl-2-Pyrimidinamin
DE69330960D1 (de) Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
DE3865368D1 (de) Thiophensulfonamide zur behandlung von glaukom.
ES2093357T3 (es) Metodo de tratamiento de la alopecia.
ATE136896T1 (de) Piperidylmethyl substituierte chromanderivate als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
DE69024060D1 (de) Osteogenesis-stimulierende mittel.
ATE204476T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
DE3767175D1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
DE69636814D1 (de) Verwendung des menschlichen choriongonadotropins in der behandlung von kaposi's-sarcoma
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
DE69431187D1 (de) 14-substituierte marcfortine und derivate als antiparasitäre mittel
NO890261D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridin-derivater.
PT84619A (de) 2,4,6-tris-tertiaerbutylamino-1,3,5-triazin zur prophylaxe und behandlung von epilepsie und angstzustaenden verwendung dieser verbindung zur herstellung eines arzneimittels sowie arzneimittel auf basis dieser verbindung
HUT54300A (en) Process for producing medicaments suitable for antiviral treatment

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI PHARMACEUTICAL CO., LTD., TOKIO/TOKYO, JP

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ATLAS PHARMACEUTICALS, INC., SUNNYVALE, CALIF., US

8339 Ceased/non-payment of the annual fee